Interventional Oncology, IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
J Vasc Interv Radiol. 2022 Mar;33(3):308-315.e1. doi: 10.1016/j.jvir.2021.11.008. Epub 2021 Nov 17.
To validate an immunofluorescence assay (IFA) detecting residual viable tumor (VT) as intraprocedural thermal ablation (TA) zone assessment and demonstrate its prognostic value for local tumor progression (LTP) after colorectal liver metastasis (CLM) TA.
This prospective study, approved by the institutional review board, included 99 patients with 155 CLMs ablated between November 2009 and January 2019. Tissue samples from the ablation zone (AZ) center and minimal margin underwent immunofluorescent microscopic examination interrogating cellular morphology and mitochondrial viability (IFA) within 30 minutes after ablation. The same tissue samples were subsequently evaluated with standard morphologic and immunohistochemical methods. The sensitivity, specificity, and overall accuracy of IFA versus standard morphologic and immunohistochemical examination were calculated. The LTP-free survival rates were evaluated for the 12-month follow-up period.
Of the 311 tissue samples stained, 304 (98%) were deemed evaluable. Of these specimens, 27% (81/304) were considered positive for the presence of VT. The accuracy of IFA was 94% (286/304). The sensitivity and specificity were 100% (63/63) and 93% (223/241), respectively. The 18 false-positive IFA assessments corresponded to samples that included viable cholangiocytes. The 12-month LTP-free survival was 59% versus 78% for IFA positive versus negative for VT AZs, respectively (P < .001). There was no difference in LTP between margin positive only and central AZ-positive tumors (25% vs 31%, P = 1).
The IFA assessment of the AZ can be completed intraprocedurally and serve as a valid real-time biomarker of complete tumor eradication or detect residual VT after TA. This method could improve tumor control by TA.
验证一种免疫荧光检测法(IFA),用于检测残余存活肿瘤(VT)作为术中热消融(TA)区域评估,并证明其对结直肠癌肝转移(CLM)TA 后局部肿瘤进展(LTP)的预后价值。
这项前瞻性研究获得了机构审查委员会的批准,共纳入了 99 例 2009 年 11 月至 2019 年 1 月期间接受消融治疗的 155 个 CLM 患者。消融后 30 分钟内,对 AZ 中心和最小边缘的组织样本进行免疫荧光显微镜检查,以检测细胞形态和线粒体活力(IFA)。随后,用标准形态学和免疫组织化学方法对相同的组织样本进行评估。计算 IFA 与标准形态学和免疫组织化学检查的敏感性、特异性和总体准确性。评估了 12 个月随访期间的 LTP 无复发生存率。
在 311 个染色组织样本中,有 304 个(98%)被认为可评估。在这些标本中,有 27%(81/304)被认为存在 VT。IFA 的准确性为 94%(286/304)。敏感性和特异性分别为 100%(63/63)和 93%(223/241)。18 次假阳性 IFA 评估对应于包含存活胆管细胞的样本。IFA 检测 VT 阳性 AZ 的 12 个月 LTP 无复发生存率为 59%,而 IFA 检测 VT 阴性 AZ 的 12 个月 LTP 无复发生存率为 78%,差异有统计学意义(P<0.001)。边缘阳性和中央 AZ 阳性肿瘤的 LTP 无差异(25%与 31%,P=1)。
AZ 的 IFA 评估可以在术中完成,作为完全肿瘤清除的有效实时生物标志物,或检测 TA 后残余 VT。这种方法可以通过 TA 提高肿瘤控制率。